Nosiheptide (NOS) is a highly modified thiopeptide antibiotic that displays formidable in vitro activity against a variety of Gram-positive bacteria. In addition to a central hydroxypyridine ring, NOS contains several other modifications, including multiple thiazole rings, dehydro-amino acids, and a 3,4-dimethylindolic acid (DMIA) moiety. The DMIA moiety is required for NOS efficacy and is synthesized from l-tryptophan in a series of reactions that have not been fully elucidated. Herein, we describe the role of NosJ, the product of an unannotated gene in the biosynthetic operon for NOS, as an acyl carrier protein that delivers 3-methylindolic acid (MIA) to NosK. We also reassign the role of NosI as the enzyme responsible for catalyzing the ATP-dependent activation of MIA and MIA's attachment to the phosphopantetheine moiety of NosJ. Lastly, NosK catalyzes the transfer of the MIA group from NosJ-MIA to a conserved serine residue (Ser102) on NosK. The X-ray crystal structure of NosK, solved to 2.3 Å resolution, reveals that the protein is an α/β-fold hydrolase. Ser102 interacts with Glu210 and His234 to form a catalytic triad located at the bottom of an open cleft that is large enough to accommodate the thiopeptide framework.
Nosiheptide (NOS) is a highly modified thiopeptide antibiotic that displays formidable in vitro activity against a variety of Gram-positive bacteria. In addition to a central hydroxypyridine ring, NOS contains several other modifications, including multiple thiazole rings, dehydro-amino acids, and a 3,4-dimethylindolic acid (DMIA) moiety. The DMIA moiety is required for NOS efficacy and is synthesized from l-tryptophan in a series of reactions that have not been fully elucidated. Herein, we describe the role of NosJ, the product of an unannotated gene in the biosynthetic operon for NOS, as an acyl carrier protein that delivers 3-methylindolic acid (MIA) to NosK. We also reassign the role of NosI as the enzyme responsible for catalyzing the ATP-dependent activation of MIA and MIA's attachment to the phosphopantetheine moiety of NosJ. Lastly, NosK catalyzes the transfer of the MIA group from NosJ-MIA to a conserved serine residue (Ser102) on NosK. The X-ray crystal structure of NosK, solved to 2.3 Å resolution, reveals that the protein is an α/β-fold hydrolase. Ser102 interacts with Glu210 and His234 to form a catalytic triad located at the bottom of an open cleft that is large enough to accommodate the thiopeptide framework.
Nosiheptide (NOS) is
one of the oldest known thiazolyl peptide
(thiopeptide) natural products and is commonly used as a feed additive
to promote growth in pigs and poultry.[1−3] It displays formidable
activity against a variety of Gram-positive bacteria of clinical relevance,
including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and vancomycin-resistant enterococci.[1] Its mode of action involves binding to the bacterial ribosome and
inhibiting translation by blocking translocation along the mRNA transcript.[2−4] Although NOS exhibits impressive in vitro activity, its use in humans
as a therapeutic agent is limited by its low solubility and poor pharmacokinetic
properties. As a result, efforts are underway to modify this natural
product, and others similar to it, via synthetic, biosynthetic, and
semisynthetic means to transform it into a useful antibacterial agent.[5,6]NOS is a highly modified sulfur-rich bicyclic peptide that
features
a central hydroxypyridine ring, from which a number of thiazole rings
and dehydro-amino acids emanate (Figure ). In addition to these core features, NOS
carries a distinguishing 3,4-dimethylindolic acid (DMIA) moiety, which
is common to the e series thiopeptides. The DMIA
moiety is appended to the thiopeptide framework via ester and thioester
linkages to the side chains of specific glutamyl and cysteinyl residues,
respectively, of a precursor peptide, generating a side ring system.[7] The NOS biosynthetic gene cluster from Streptomyces actuosus was identified by Liu and co-workers,
and is composed of 16 genes, which are designated nosA-nosP (Figure A).[8] The thiopeptide framework
is ribosomally synthesized as a precursor peptide, which is encoded
by the nosM gene. NosM is a peptide of 50 amino acids
(aa), in which residues 1–37 constitute a leader peptide that
is important in recognition by several enzymes that catalyze the extensive
post-translational modifications. The remaining 13 C-terminal aa compose
a structural peptide of sequence SCTTCECCCSCSS. NosD,
E, F, G, H, and O are postulated to be involved in generation of the
thiopeptide framework, given that homologues are found in operons
for the biosyntheses of similar thiopeptides in other organisms.[3] NosG and NosH function as a complex to catalyze
cyclodehydration, whereas NosF is a dehydrogenase. Together, they
catalyze formation of the thiazole rings of NOS. NosE and NosD work
sequentially to give rise to the dehydro-amino acids. NosO, which
shares ∼30% sequence identity with TbtD, shown to generate
the nitrogen-containing six-membered heterocycle in thiomuracin,[9,10] most likely generates the analogous heterocycle in NOS (Figure ).
Figure 1
Structure of nosiheptide
featuring the dimethylindolic acid (DMIA)
moiety (red).
Figure 2
(A) nos operon. (B) Postulated pathway for formation
of the DMIA moiety of NOS.
Structure of nosiheptide
featuring the dimethylindolic acid (DMIA)
moiety (red).(A) nos operon. (B) Postulated pathway for formation
of the DMIA moiety of NOS.The encoded proteins, NosA, B, and C, are tailoring enzymes.
NosA
generates the C-terminal amide group of the thiopeptide,[11] whereas NosB and NosC, annotated as cytochrome
P450-like enzymes, hydroxylate the γ-carbon of the
glutamyl residue, and C3 of the nitrogen-containing heterocycle, respectively.[12] Lastly, NosI, J, K, L, and N are involved in
the biosynthesis and attachment of the DMIA moiety of NOS.A
scheme for formation and attachment of the DMIA moiety of NOS
has been advanced by Liu and colleagues, and is shown in Figure B.[8] It is well established that NosL catalyzes the initial
step in the pathway, which is a radical-dependent conversion of tryptophan
(Trp) to 3-methylindolic acid (MIA).[13] MIA
was then suggested to be converted to its AMP or CoA derivative by
an undesignated enzyme, after which, NosN appends a methyl group to
C4 of MIA to give DMIA. NosK, annotated as a member of the α/β-fold
hydrolase family, was predicted to attach DMIA to the appropriate
cysteinyl residue of the thiopeptide framework, and an undesignated
protein (most likely NosB or NosC) was predicted to hydroxylate C4
of DMIA. Lastly, NosI, annotated as an AMP-dependent acyl-CoA synthetase/ligase,
was predicted to activate the glutamyl residue in the structural peptide
by adenylation and catalyze the last step in formation of the minor
macrocycle by facilitating attack of the C4 hydroxyl group onto the
activated glutamyl residue to generate the ester linkage.[13] The authors also noted that NosN might not act
directly on MIA, but rather after MIA has been attached to the cysteinyl
residue of the NOS thiopeptide framework (Figure B). Though the postulated pathway for NOS
biosynthesis is enticing, certain issues stand out. For example, only
two cytochrome P450 enzymes are encoded in the nos operon (NosB and NosC) and both have assigned functions
(see above).[12] Therefore, no reasonable
candidates to hydroxylate C4 of DMIA are encoded in the nos operon. Moreover, although Floss and colleagues showed that DMIA,
administered externally to growing S. actuosus, was incorporated into intact NOS, C4-hydroxymethyl-MIA was not.[14]Our interest in nosiheptide biosynthesis
stems from the predicted
activity of NosN, which has been suggested to methylate C4 of an MIA
moiety during nosiheptide biosynthesis. NosN is annotated as a radical S-adenosylmethionine (SAM) enzyme, meaning that it uses
the oxidative power of a 5′-deoxyadenosyl 5′-radical
(5′-dA·) to initiate radical-based transformations. The
5′-dA· derives from SAM via a reductive fragmentation
reaction that requires the participation of a [4Fe–4S] cluster,
a metallocofactor that is common among all enzymes of the radicalSAM (RS) superfamily. One of the emerging areas in RS enzymology is
the methylation of unactivated carbon or phosphinate phosphorus atoms.
Several strategies have become apparent, and the choice of which to
use appears to depend on the structure of the substrate and the hybridization
of the carbon atom (sp2- or sp3-hybridized) undergoing methylation. NosN is a member
of Class C RS methylases, which are understudied, because they tend
to operate on complex natural products.[15,16] The work described
herein details our efforts to identify the substrate for NosN, which
has led us to revise the pathway by which DMIA of NOS is biosynthesized.
Results
Characterization
of NosJ
In the original description
of proteins encoded by the nos operon for NOS biosynthesis,
NosJ was not attributed a function. The nosJ open
reading frame (orf), however, encodes for a protein of 79 aa with
a molecular mass (Mr) of 8849 Da, which
is similar to the Mr of an acyl carrier
protein (ACP).[17,18] For example, Escherichia
coli acyl carrier protein, AcpP, is composed of 78
aa and has an Mr of 8640 Da. AcpP does
not contain any cysteinyl residues, but the protein is post-translationally
modified at Ser-37 with a 4′-phosphopantetheine group, which
terminates in a sulfur atom. In AcpP, Ser-37 is found in a DSLDTV motif, present in NosJ as
DSLETV.[17,18] A BLAST analysis of NosJ using
default parameters in UniProt yielded best matches with several other
proteins from Streptomyces, including an uncharacterized protein from Streptomyces afghaniensis 772; the C-terminal region
of NocK from Nocardia Sp., which is
involved in nocathiacin biosynthesis, another thiopeptide antibiotic;
TsrI from Streptomyces laurentii, which
is involved in thiostrepton biosynthesis; and SioP from Streptomyces sioyaensis, which is involved in siomycin
biosynthesis. All of these organisms produce thiopeptide antibiotics
that contain side ring systems containing appendages derived from
tryptophan, either DMIA (NOS and nocathiacin) or a quinaldic acid
moiety (thiostrepton and siomycin).[2,3]To determine
whether NosJ is an ACP, the protein was overproduced heterologously
in E. coli and then purified using
procedures similar to those used to isolate E. coli ACP.[19,20] The protein is >95% pure after anion-exchange
chromatography using DE-52 resin and gel-filtration chromatography
using a Sephacryl S-200 HR 26/60 prepacked column (Figure S1). Analysis of the protein by electrospray-ionization
mass spectrometry in positive mode (ESI+-MS) shows that
it exhibits an Mr of 8717 Da, which is
consistent with the theoretical Mr (8717.63
Da) after accounting for removal of the N-terminal methionine (Figure , panel 1). A small
(∼10%) portion of NosJ displays a molecular mass of 9048 Da
(theoretical mass is 9057.96 Da), which is consistent with the addition
of a 4′-phosphopantheine group (340.34 Da) to the protein during
its overproduction in E. coli. To generate
a larger fraction of the phosphopantetheinylated form of NosJ (i.e.,
holo NosJ), the protein was incubated for 30 min at room temperature
with E. coli holo ACP synthase, which
catalyzes the transfer of the 4′-phosphopantetheine group from
coenzyme-A to the target seryl residue to afford holo ACP.[18,21] As shown in panel 2 of Figure , the peak at Mr 8717 Da
decreases in intensity, whereas the peak at Mr 9058 Da increases in intensity. The observed mass of NosJ
and its capacity to be modified with a phosphopantetheine prosthetic
group, both in E. coli and as a purified
protein, indicate that NosJ is an ACP.
Figure 3
Characterization of NosJ
and NosK. Panel 1 shows as-purified NosJ
(theoretical mass is 8717.63 Da). Panel 2 displays the mass shift
corresponding to the transfer of 4′-phosphopantetheine to NosJ
to produce holo NosJ (theoretical mass is 9057.96 Da). Panel 3 shows
the NosI-dependent transfer of MIA to NosJ to produce MIA-holo NosJ
(theoretical mass is 9215.13 Da). Finally, upon incubation with NosK,
MIA-holo NosJ is reverted back to holo NosJ due to MIA transfer to
NosK (Panel 4). The proposed reaction scheme is shown at bottom left.
Characterization of NosJ
and NosK. Panel 1 shows as-purified NosJ
(theoretical mass is 8717.63 Da). Panel 2 displays the mass shift
corresponding to the transfer of 4′-phosphopantetheine to NosJ
to produce holo NosJ (theoretical mass is 9057.96 Da). Panel 3 shows
the NosI-dependent transfer of MIA to NosJ to produce MIA-holo NosJ
(theoretical mass is 9215.13 Da). Finally, upon incubation with NosK,
MIA-holo NosJ is reverted back to holo NosJ due to MIA transfer to
NosK (Panel 4). The proposed reaction scheme is shown at bottom left.
Characterization of NosI
ACPs typically function as
molecular carriers. In fatty acid biosynthesis, they serve as the
template upon which fatty acyl chains are elongated.[22] In nonribosomal peptide synthetases (NRPSs) and polyketide
synthetases (PKSs), ACPs exist as carrier or thiolation domains (TDs).[23] In PKSs, acyl-CoAs existing as primary metabolites
are attached to TDs via transthioesterification reactions. In NRPSs,
however, amino acids and other metabolites that do not exist naturally
as CoA-thioesters must first be activated in an ATP-dependent fashion
to give an intermediate amino acid–adenylate species, which
is then used to generate the corresponding TD-amino acid thioester.[23] In the nos operon, NosI is
annotated as requiring ATP (AMP-dependent acyl-CoA synthetase), suggesting
that it might be involved in the activation and transfer of MIA to
holo NosJ. The nosI gene was therefore cloned such
that its product would be produced with an N-terminal hexahistidine
(His6) tag upon expression to facilitate purification by
immobilized metal affinity chromatography (IMAC). The protein was
purified to >90% homogeneity with a yield of ∼30 mg from
30
g of E. coli cell paste (Figure S2). The addition of 5 mM ATP to purification
buffers was critical for improving the solubility of the protein.To assess whether NosI activates MIA, NosI was incubated with 1 mM
MIA and 1 mM ATP in HEPES buffer, pH 7.5, and formation of the MIA-adenylate
was assessed at designated times by ESI+-MS (Figure A). A burst phase of MIA-AMP
production is observed that is followed by a second phase that is
nearly horizontal, suggesting that no additional product formation,
or extremely slow product formation, takes place after the initial
burst. When the experiment is conducted with varying concentrations
of NosI (2, 4, or 8 μM), the amplitudes of the burst phases
vary linearly with those concentrations, suggesting that the enzyme
catalyzes only one turnover under the conditions described (Figure A,B). This behavior
suggests that NosI catalyzes both the activation of MIA and its subsequent
transfer to some target.
Figure 4
Reaction of NosI with ATP and MIA. ATP (1 mM)
and MIA (1 mM) were
incubated with 2 (red triangles), 4 (black triangles), 8 μM
(green triangles) NosI in the absence of NosK for varying lengths
of time (15 to 800 s), and MIA-AMP was measured by LC-MS as a relative
integrated response (A). Amplitudes from each of the time courses
plotted as a function of NosI concentration show a linear correlation
(B). The reactions were conducted in an ice–water bath.
Reaction of NosI with ATP and MIA. ATP (1 mM)
and MIA (1 mM) were
incubated with 2 (red triangles), 4 (black triangles), 8 μM
(green triangles) NosI in the absence of NosK for varying lengths
of time (15 to 800 s), and MIA-AMP was measured by LC-MS as a relative
integrated response (A). Amplitudes from each of the time courses
plotted as a function of NosI concentration show a linear correlation
(B). The reactions were conducted in an ice–water bath.To assess whether holo NosJ is
the NosI-dependent acceptor of MIA,
NosI was incubated with MIA, ATP, and NosJ, and formation of NosJ-MIA
was assessed by HPLC. As shown in Figure (Trace B), apo and holo NosJ migrate at
retention times of 9.8 (black trace) and 10.6 min (blue trace), respectively,
under the conditions described in the Experimental
Procedures. When holo NosJ is incubated with NosI, ATP, and
MIA, this retention time shifts to 19.3 min, indicating the modification
of holo NosJ with MIA (Figure , Trace F). Omission of NosI (Trace C), ATP (Trace D), or
MIA (Trace E) from the reaction mixture does not result in a shift,
in the retention time of holo NosJ, verifying that all of these components
are required for modification of holo NosJ. Analysis of NosJ by mass
spectrometry after incubating it with NosI, MIA, and ATP revealed
it to exhibit an m/z of 9215 (Figure , panel 3), which
is consistent with the theoretical mass of MIA-NosJ (9215.13 Da).
Figure 5
HPLC analysis
of holo NosJ upon reaction with ATP, MIA, and NosI.
(A) apo NosJ; (B) holo NosJ; (C) holo NosJ + ATP and MIA; (D) holo
NosJ + NosI and MIA; (E) holo NosJ + NosI and ATP; and (F) holo NosJ
+ NosI, MIA, and ATP (complete reaction).
HPLC analysis
of holo NosJ upon reaction with ATP, MIA, and NosI.
(A) apo NosJ; (B) holo NosJ; (C) holo NosJ + ATP and MIA; (D) holo
NosJ + NosI and MIA; (E) holo NosJ + NosI and ATP; and (F) holo NosJ
+ NosI, MIA, and ATP (complete reaction).
Characterization of NosK
In the nos operon, nosJ is adjacent to nosK. In the noc operon, which encodes proteins that
are involved in the biosynthesis of nocathiacin, a related thiopeptide
antibiotic, the encoded NocJ and NocK proteins are part of the same
polypeptide. These observations suggest that NosJ and NosK might have
related activities. Therefore, hexahistidine-tagged NosK was purified
to homogeneity (100 mg from 10 g of E. coli cell paste) by IMAC (Figure S3) and characterized.
As shown in Figure (blue trace), NosK migrates at a retention time of 7.6 min under
the conditions described in the Experimental Procedures. The addition of holo NosJ, MIA, and ATP to NosK results in essentially
no change in retention time (Figure black trace). However, the addition of NosI to holo
NosJ, MIA, ATP, and NosK results in a change in NosK’s retention
time from 7.6 to 10 min. When NosK is then digested with trypsin and
subjected to mass spectrometry, a peptide is observed (LIGASYLGGPLAHR) that contains MIA covalently
bound to the side-chain of Ser102 (Table S1). In a control reaction, in which ATP is omitted, the same peptide
is observed but without the MIA linkage (Table S2).
HPLC analysis of the acylation of NosK. NosK, blue; NosK + NosJ,
black; NosK + NosJ + NosI, pink; NosK Ser102Ala variant, red; NosK
Ser102Ala variant + NosJ + NosI, green.To confirm the role of Ser102 as an acyl acceptor, the amino
acid
was changed to alanine and the resulting NosK variant was substituted
in the reaction. NosK S102A migrates slightly slower than wild-type
NosK, exhibiting a retention time of 8.3 min rather than 7.7 min (Figure , red trace). When
the NosK S102A variant is incubated with holo NosJ, ATP, MIA, and
NosI, no shift in retention time is observed, which is consistent
with Ser102 as the intermediate acyl acceptor site. This role for
NosK is also consistent with observations reported in Figure (panel 4), wherein the addition
of NosK to a reaction containing NosI, NosJ, MIA, and ATP results
in the conversion of MIA-NosJ to holo NosJ.
Determination of the X-ray
Crystal Structure of NosK
The structure of NosK was solved
to 2.3 Å resolution by X-ray
crystallography (Figure A, PDB accession code 5V7O). The protein exhibits an α/β hydrolase
fold, as anticipated from initial bioinformatic annotation and is
consistent with its experimentally determined acyltransferase function.
The site of MIA attachment, Ser102, is found to be part of a catalytic
triad involving His234 and Glu210 (Figure B). In other α/β hydrolases,
the Ser nucleophile is located at the apex of a tight β-to-α
transition, termed the nucleophile elbow, that is facilitated by a
strictly conserved consensus Sm-X-Nu-X-Sm (X = any amino acid, Sm
= Gly/Ala) motif.[24] In NosK, Ser102 is
found instead in a GASYLG
sequence, which deviates from the consensus via insertion of an additional
hydrophobic residue following the nucleophile. The insertion extends
the turn by one residue, allowing the neighboring Tyr side chain to
partially occlude the Ser nucleophile (Figure C). This modification to the consensus sequence
is also found in the N-terminal region of Nocardia NocK and may be linked to the proposed acyltransferase function
of the two enzymes. Insertion of a bulky side chain could promote
retention of the acyl-enzyme intermediate via local protection from
solvent to prevent unwanted attack by water molecules. The insertion
is also found in several of the closest homologues to NosK identified
in a BLAST search, many of which are uncharacterized but currently
annotated as hydrolases.
Figure 7
(A) Ribbon diagram of the overall structure
of NosK, featuring
the core α/β hydrolase domain and the cap domain. The
catalytic triad is shown in yellow stick format. (B) NosK Ser-His-Glu
catalytic triad. (C) Overlay of the nucleophile elbow in BioH (PDB
accession code 4ETW)[28] (tan) and NosK (white) showing insertion
of Tyr103 near the Ser102 nucleophile.
(A) Ribbon diagram of the overall structure
of NosK, featuring
the core α/β hydrolase domain and the cap domain. The
catalytic triad is shown in yellow stick format. (B) NosK Ser-His-Glu
catalytic triad. (C) Overlay of the nucleophile elbow in BioH (PDB
accession code 4ETW)[28] (tan) and NosK (white) showing insertion
of Tyr103 near the Ser102 nucleophile.In addition to the α/β hydrolase domain, NosK
contains
an ancillary cap domain composed of three short alpha helices inserted
between β4 and α4 in the core hydrolase fold (Figure A, right panel).
Although the general domain architecture is typical of the haloalkane
dehalogenase (HAD) subfamily,[25] the cap
motif in NosK is particularly small owing to truncation of the cap
secondary structures. The cap region borders the NosK active site,
generating a wide shallow groove, presumably for substrate interaction,
that is ∼25 Å long and 17 Å wide. The arrangement
yields a highly exposed catalytic triad when compared to prototypical
HAD-type hydrolases with larger cap structures (Figure A–C, left panels).[26] The open state may facilitate interaction with protein/peptide-based
substrates such as the MIA-NosJ ACP complex and the thiopeptide acceptor.
Query of the DALI structural comparison database reveals a similar
abbreviated cap domain in human drug metabolism enzyme valacyclovirase,
an amino acid esterase with broad substrate specificity.[27] In that system, the open active site structure
is functionally relevant and responsible for the ability to bind a
diverse spectrum of target molecules. Despite the small NosK-like
cap structure, the catalytic triad in valacyclovirase remains less
solvent exposed than the NosK active site. As in most other HAD-type
hydrolases, valacyclovirase contributes an Asp as the third acidic
component of the catalytic triad from a loop structure that blocks
the active site distal to the cap domain. NosK instead uses a longer
Glu side chain contributed by a helix within the core fold (Figure S4). The alternative mechanism of catalytic
triad formation allows open access to the active site from two different
directions in NosK.
Figure 8
Space-filling and cartoon models of NosK (A) and two structurally
similar proteins, MCP hydrolase (PDB accession code 4LXG)[26] (B) and valacyclovirase (PDB accession code 2OCG)[27] (C). Cap domain shown in yellow and catalytic serine (left)
or triad (right) shown in green.
Space-filling and cartoon models of NosK (A) and two structurally
similar proteins, MCP hydrolase (PDB accession code 4LXG)[26] (B) and valacyclovirase (PDB accession code 2OCG)[27] (C). Cap domain shown in yellow and catalytic serine (left)
or triad (right) shown in green.The NosK cap domain itself may be directly involved in interaction
with NosJ, a mode of complex formation with precedent in the biotin
biosynthesis pathway (Figure A).[28] BioH is a HAD-type α/β
hydrolase that cleaves the terminal methyl ester of an 8-carbon fatty
acid substrate attached to an ACP-phosphopantetheine carrier. BioH
harbors a typical large cap domain that occludes the nucleophilic
Ser. The ACP binding partner sits on top of the cap domain, threading
the linear fatty acid tail through a substrate channel to the active
site. The structure suggests a model for NosJ interaction with the
smaller NosK cap domain in which the open active site cavity may be
better suited to accommodate the bulkier MIA appendage. Analysis of
the NosK electrostatic surface potential in the vicinity of the Ser102
nucleophile indicates the active site cavity is largely hydrophobic
but flanked by regions of positive and negative charge (Figure S5). The charged regions could be important
for directing the MIA-NosJ donor and peptide acceptor to different
parts of the active site.
Figure 9
Structures of ACP-BioH (A) (PDB accession code 4ETW)[28] and NosK (B). In BioH, the cap domain has been shown to
mediate the binding of ACP tethered to a phosphopantetheine-fatty
acid substrate (Ppant, aqua).
Structures of ACP-BioH (A) (PDB accession code 4ETW)[28] and NosK (B). In BioH, the cap domain has been shown to
mediate the binding of ACP tethered to a phosphopantetheine-fatty
acid substrate (Ppant, aqua).
Discussion
The thiopeptide natural products have recently
received a tremendous
amount of attention due to their potent in vitro activities against
a variety of Gram-positive pathogens of significant clinical relevance.
Their practical use in humans has been hampered, however, by poor
solubility and poor pharmacokinetic properties, mandating generation
of more practical analogs of these natural products by synthetic,
biosynthetic, and semisynthetic methods.[2,3,5] Pioneering studies by Liu and colleagues led to the
identification of the operon for nosiheptide biosynthesis and the
discovery that the natural product is derived from a ribosomally synthesized
peptide.[8] In the model put forth by the
Liu laboratory (Figure b), NosK functions to transfer an MIA or a DMIA moiety from a CoA-
or an AMP-linked precursor to Cys-8 of the structural peptide. In
the event that MIA is transferred rather than DMIA, then NosN would
methylate this species to give DMIA. Next, the C4 methyl moiety of
the DMIA moiety was suggested to be hydroxylated by one of two P450 enzymes. Lastly, Glu-6 of the structural peptide was postulated
to be adenylated by NosI, allowing the C4 hydroxyl group of DMIA to
displace the adenylate and form the ester linkage of the side-ring
system.Our own studies indicate a different route for attachment
of the
indolic acid moiety to the thiopeptide framework of nosiheptide. We
functionally assigned NosJ, for the first time, as an ACP that plays
an integral role in DMIA synthesis and transfer, and characterized
NosI as the protein that activates MIA for transfer to the phosphopantetheine
prosthetic group of NosJ. Lastly, a conserved seryl residue (Ser102)
on NosK, which anchors a Ser-His-Glu catalytic triad, accepts the
MIA group from ACP and presumably transfers it to the thiopeptide
framework at some stage of its maturation. The structure of NosK is
consistent with this postulated role. Its active site contains a shallow
groove that is formed at the interface of the α/β hydrolase
and cap domains. The cap domain most likely participates in the binding
of NosJ to NosK, as is observed in the structure of the similar enzyme
BioH. The rectangular groove shape in NosK may also be particularly
well-suited to interact with a linear thiopeptide in the second half
of the acyl-transfer reaction.We have some insight into the
timing of DMIA incorporation from
recent studies of nosiheptide biosynthesis in S. actuosus, in which nosO was deleted in a strain of the native
producer bacterium that had several copies of the gene encoding NosM
present in trans. This approach led to the identification
and characterization of a low-yield off-pathway intermediate that
lacked the six-membered heterocycle in nosiheptide, but which contained
fully installed thiazoles and dehydro-amino acids. As expected, the
large macrocycle was not formed, given that the six-membered heterocycle
is involved in the connections that form the macrocycle; however,
the smaller side ring system, in which Glu-6 and Cys-8 are bridged
by the DMIA moiety, was present. No other post-translational modifications
were observed, suggesting that they are not required for transfer
of MIA or DMIA to the thiopeptide framework or for formation of the
side ring system.[29] Moreover, previous
studies indicate that transfer of the MIA/DMIA moiety to the thiopeptide
framework is necessary for formation of the core macrocycle and that
NosI plays a key role in this process.[8,30] Together,
these results and observations suggest that the NosK-mediated transfer
of the MIA/DMIA moiety to the thiopeptide framework occurs before
formation of the six-membered heterocycle: either directly on NosM,
on NosM after thiazole formation, or on NosM both after thiazole formation
and after formation of dehydro-amino acids. We posit that NosN acts
subsequently, catalyzing both the transfer of a C1 unit to C4 of MIA
and the formation of the side ring.Very recent studies from
the Zhang group have shed some light on
the mechanism of NosN,[31] which is a Class
C RS methylase, and is therefore expected to bind two molecules of
SAM simultaneously to effect its reaction.[15,16] The authors found that one SAM molecule is used to generate a 5′-dA·
that is used to abstract a hydrogen atom from what was originally
hypothesized to be the methyl moiety of the second SAM molecule. Unexpectedly,
the authors also found that the second SAM molecule is first converted
into methylthioadenosine (MTA) before hydrogen-atom abstraction takes
place from the methyl moiety of MTA. They postulated the formation
of a key species containing a delocalized electron (Figure , I) that is
formed upon addition of a 5′-methylthioadenosine-5′-methylthio
radical to C4 of MIA and subsequent elimination of 5′-thioadenosine.
This intermediate is postulated to rearrange to the methylated product
upon gain of an electron and a proton. Given that there are no additional
P450-like enzymes encoded by genes in the nos operon, needed to hydroxylate the C4 methyl moiety of the DMIA group
according to the pathway shown in Figure , as well as our finding that NosI activates
the carboxyl group of MIA, we suggest that NosN catalyzes both formation
of the intermediate I and subsequent formation of the
ester linkage between Glu-6 of the thiopeptide and C4 of the DMIA
moiety. This reaction could arise by loss of an electron from intermediate I to generate the electrophile II. Finally, attack
of the carboxyl moiety of Glu-6 onto the exocyclic methylene of II
completes formation of the side ring system.
Figure 10
Postulated mechanism
for NosN-catalyzed formation of side-ring
system.
Postulated mechanism
for NosN-catalyzed formation of side-ring
system.
EXPERIMENTAL PROCEDURES
Materials
All DNA-modifying enzymes and reagents used
were purchased from New England Biolabs. DNA isolation kits were purchased
from Machery-Nagel. The nosI, nosJ, and nosK genes, optimized for expression in E. coli, were purchased from ThermoFisher Scientific. PfuTurbo DNA polymerase AD was purchased from Agilent Technologies
Inc. Sequencing grade trypsin was purchased from Promega Corporation.
Primers were purchased from Integrated DNA Technologies. Deoxynucleotides
were purchased from Denville Scientific Corporation. The expression
vectors, pET-26b and pET-28a, were purchased from EMD Millipore. N-(2-hydroxyethyl)piperizine-N′-(2-ethanesulfonic
acid) (HEPES) was purchased from Fisher Scientific. Imidazole, trifluoroacetic
acid (TFA), and 2-(N-morpholino)ethanesulfonic acid
hydrate (MES) were purchased from J. T. Baker Chemical Co. Potassium
chloride and glycerol were purchased from EMD Chemicals. 2-Mercaptoethanol
and phenylmethanesulfonyl fluoride (PMSF) were purchased from Sigma–Aldrich.
Isopropyl β-d-1-thiogalactopyranoside (IPTG) and dithiothreitol
(DTT) were purchased from Gold Biotechnology. ATP (disodium salt)
and coenzyme A (trilithium salt) were purchased from Calbiochem. 3-Methyl
indolic acid (MIA) was purchased from Matrix Scientific. Talon metal
affinity resin was acquired from Clontech Laboratories Inc., and DE-52
anion-exchange resin was from GE Lifesciences. All other chemicals
and materials were of the highest grade available.
General Methods
DNA sequencing was carried out at the
Pennsylvania State University Genomic Core facility. UV–visible
spectra were recorded on a Cary 50 spectrometer from Varian (Walnut
Creek, CA) using the WinUV software package to direct the instrument
and manipulate the data. High-performance liquid chromatography (HPLC)
was conducted on an Agilent 1100 Series system coupled with an Agilent
1100 Series variable wavelength detector and quaternary pump. Polymerase
chain reactions (PCR) were performed using a robocylcer gradient 40
thermal cycler from Stratagene.
Cloning of the nosI Gene
into pET-28a
The gene encoding nosI was
codon-optimized for expression in E. coli and was delivered as a construct in plasmid
pMK-RQ. The gene contained two restriction sites, NdeI (5′ end) and EcoRI (3′ end), and
was cloned into the same restriction sites of a pET-28a vector. The nosI gene was expressed as a fusion protein with an N-terminal
hexahistidine (His6) tag. The codon-optimized gene sequence
of nosI, with the NdeI and EcoRI restriction sites indicated in bold type, is provided
in the Supporting Information.
Cloning of
the nosJ Gene into pET-26b
The gene encoding nosJ was codon-optimized for expression in E. coli and was delivered as a construct in plasmid
pMA-T. The gene contained two restriction sites, NdeI (5′ end) and EcoRI (3′ end), with
a stop codon just before the EcoRI site. The gene
was excised by digestion with NdeI and EcoRI and cloned into a pET-26b vector that was digested with the same
two enzymes. The codon-optimized gene sequence of nosJ, with the NdeI and EcoRI restriction
sites indicated in bold type, is provided in the Supporting Information.
Cloning of the nosK Gene
into pET-28a
The gene encoding nosK was
codon-optimized for expression in E. coli and was delivered as a construct in plasmid
pMA-T. The gene contained two restriction sites, NdeI (5′ end) and EcoRI (3′ end), and
was cloned into the same restriction sites of a pET-28a vector. The
listed primers were used to introduce a stop codon at amino acid position
271. The nosK gene was expressed as a fusion protein
with an N-terminal hexahistidine tag. The codon-optimized gene sequence
of nosK, with the NdeI and EcoRI restriction sites indicated in bold type, is provided
in the Supporting Information.
Construction
of the NosK Ser102Ala Variant
The gene
encoding the Ser102Ala variant was constructed by the polymerase chain
reaction. The reaction contained 200 ng of template, 0.4 μM
forward primer (5′-GGTCCGGGTCGTCTGATTGGTGCAGCGTATCTGGGTGGTCCGCTGGC),
0.4 μM reverse primer (5′-GCCAGCGGACCACCCAGATACGCTGCACCAATCAGACGACCCGGACC-3′),
250 μM each dNTP, 1× PfuTurbo DNA polymerase
buffer, and 2.5 U of PfuTurbo DNA polymerase AD in
a total of 50 μL. The reaction was heated at 95 °C for
5 min to denature the template. Next, 16 cycles of denaturation, annealing,
and extension were performed at 95 °C for 1 min, 55 °C for
1.5 min, and 68 °C for 15 min, respectively. A final extension
was performed at 68 °C for 10 min.
Overproduction and Purification
of NosI
E. coliBL-21 (DE3)
was transformed with plasmids
encoding NosI. An LB media starter culture was inoculated with a single
colony and incubated overnight (250 rpm at 37 °C). Several shake
flasks of LB media were then inoculated with the overnight starter
culture to initiate growth (180 rpm at 37 °C). Gene expression
was induced with 0.5 mM IPTG at an OD600 of ∼0.6,
and the flasks were subsequently placed in an ice bath for 1 h. Once
cooled, the cultures were incubated overnight (approximately 18 h)
at 18 °C with shaking at 180 rpm. The cells were harvested (∼30
g), flash frozen in liquid nitrogen, and stored −80 °C.For purification, 30 g of cell paste was resuspended in 150 mL
of lysis buffer (50 mM HEPES, pH 7.5, 300 mM KCl, 10% glycerol, 5
mM ATP, and 10 mM BME) containing PMSF (1 mM), DNase1 (100 μg
mL–1), and lysozyme (1 mg mL–1). Once the cells were resuspended, they were placed in an ice-bath
and subjected to 6 sonication bursts (40% output) of 45 s with 8 min
pauses between bursts to allow the temperature to re-equilibrate.
The lysate was then centrifuged for 1 h at 50,000g at 4 °C. The resulting supernatant was loaded onto a Talon
cobalt resin column already equilibrated with 100 mL of lysis buffer.
The loaded column was washed twice with 100 mL of lysis buffer before
eluting it with 50 mL of elution buffer (50 mM HEPES, pH 7.5, 300
mM KCl, 250 mM imidazole, 10% glycerol, 1 mM ATP, and 10 mM BME).
Two 20 mL fractions were concentrated using an Amicon Ultra centrifugal
filter unit (Millipore; Billerica, MA) with a 10-kDa molecular weight
cutoff membrane. The protein was purified further by passing it over
a 16/60 S-200 column equilibrated in 300 mM KCl, 50 mM HEPES, pH 7.5,
1 mM ATP, 1 mM DTT, and 20% glycerol. The protein was then concentrated
in the same manner as described above. The concentration of protein
was estimated by the Bradford assay.[32] The
protein was flash frozen in microcentrifuge tubes and stored at −80
°C. The total yield is ∼15 mg from 30 g of frozen cell
paste.
Overproduction and Purification of NosJ
Plasmids encoding
NosJ were transformed into BL-21 (DE3). An LB media starter culture
was then inoculated with a single colony and incubated overnight with
shaking (250 rpm) at 37 °C. Several 6 L shake flasks of LB media
were then inoculated with the overnight starter culture and agitated
at 180 rpm and 37 °C. Gene expression was induced with 1 mM IPTG
at an OD600 of ∼0.6, and the flasks were subsequently
placed in an ice bath for 1 h. Once cooled, the cultures were incubated
overnight (approximately 18 h) at 18 °C with shaking (180 rpm).
The cells were harvested (∼30 g), flash frozen in liquid nitrogen,
and stored in a liquid nitrogen dewar until purification.For
purification, 30 g of cell paste was resuspended in 150 mL of lysis
buffer (50 mM Tris–HCl, pH 8.4) containing DNase1 (100 μg
mL–1) and lysozyme (1 mg mL–1).
Once resuspended, the mixture was placed in an ice bath and sonicated
(40% output) for 45 s with 7 min pauses between bursts, for a total
sonication time of 6 min. The lysate was then centrifuged at 35,000g for 1 h at 4 °C. The final supernatant was then diluted
with 1 volume of 50 mM MES, pH 6.1, and then loaded onto a DE-52 anion-exchange
column equilibrated in 50 mM MES buffer, pH 6.1. Once loaded, the
column was washed with 1 L of 50 mM MES, pH 6.1, and the protein was
eluted with a linear 1 L gradient of 0 to 0.50 M KCl in 50 mM MES,
pH 6.1. Fractions were analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and those containing significant amounts
of NosJ (350 mL total volume) were pooled and concentrated in an Amicon
stirred cell with a 3-kDa molecular weight cutoff membrane. The concentrated
protein was further purified on a HiPrep 26/60 S-200 column equilibrated
in 25 mM HEPES, pH 7.5, 10% glycerol, and 300 mM KCl. The protein
was concentrated using an ultracentrifugal filter, flash frozen in
liquid nitrogen, and stored in a liquid nitrogen dewar. The final
concentration was determined using an extinction coefficient of 12 490
L mol–1 cm–1 mol at 280 nm, which
was determined from the sequence of NosJ using the ProtParam tool
from the ExPASy Proteomics Resource Portal (http://web.expasy.org/protparam/). The final yield was ∼60 mg from 30 g of cell paste.
Overproduction
and Purification of WT NosK and the NosK Ser102Ala
Variant
Plasmids encoding WT NosK or the NosK Ser102Ala variant
were transformed into E. coliBL-21
(DE3). An LB media starter culture was then inoculated with a single
colony and incubated overnight at 37 °C with shaking at 250 rpm.
Several shake flasks of LB media were then inoculated with the overnight
starter culture to initiate growth (180 rpm at 37 °C). Gene expression
was induced with 1 mM IPTG at an OD600 of ∼0.6,
and the flasks were immediately placed in an ice bath for 1 h. Once
cooled, the cultures were incubated overnight for 18 h at 18 °C
with shaking at 180 rpm. The cells were harvested (∼20 g),
flash-frozen in liquid nitrogen, and stored at −80 °C.For purification, 20 g of frozen cell paste was resuspended in
150 mL of lysis buffer (50 mM HEPES, pH 7.5, 300 mM KCl, 10% (v/v)
glycerol, and 10 mM BME) containing PMSF (1 mM), DNase1 (100 μg
mL–1), and lysozyme (1 mg mL–1). Resuspended cells were incubated on ice and subjected to six sonication
bursts on a QSonica instrument (40% output) for 45 s each with 8 min
intermittent pauses. The lysate was then centrifuged for 1 h at 50,000g at 4 °C. The supernatant was then loaded onto Talon
Co(2+) resin equilibrated in the lysis buffer. The resin
was washed twice with 100 mL of the lysis buffer prior to elution
of His-tagged NosK with 50 mL of elution buffer (50 mM HEPES, pH 7.5,
30 mM KCl, 250 mM imidazole, 10% (v/v) glycerol, and 10 mM BME). The
pooled eluate was concentrated by ultracentrifugation using an Amicon
Ultra centrifugal filter unit with a 10-kDa molecular weight cutoff
membrane. The protein was purified further by passage over a HiPrep
16/60 S200 column equilibrated in 300 mM KCl, 50 mM HEPES, pH 7.5,
1 mM DTT, and 10% (v/v) glycerol. The protein was then concentrated
in this buffer as described above and stored in liquid nitrogen. The
final concentration of NosK was estimated by UV–vis spectroscopy
using an extinction coefficient of 29 450 L mol–1 cm–1 at 280 nm obtained using the ProtParam tool
of the ExPASy proteomics resource portal (http://web.expasy.org/protparam/). The final yield was ∼100 mg of protein per 20 g of cell
paste.
NosI Activity Determinations
Reaction mixtures contained
25 mM HEPES, pH 7.5, 1 mM ATP, 1 mM MIA, and varying concentrations
of NosI (2, 4, and 8 μM), and were performed in triplicate.
All reaction components except MIA were mixed and then equilibrated
in an ice–water bath in which the reactions were conducted.
Reactions were initiated by the addition of MIA, and at designated
times, 10 μL aliquots were removed and added to 10 mL of a solution
containing 100 μM tryptophan (internal standard) and 50 mM H2SO4 to quench the reaction. Products were then
analyzed by HPLC with detection by mass spectrometry (LC-MS).
LC-MS
Method
HPLC with detection by positive-mode electrospray-ionization
(ESI+) mass spectrometry was conducted on an Agilent Technologies
1260 system coupled to an Agilent Technologies 6460 triple-quad mass
spectrometer. The associated MassHunter software package was used
to operate the system and to collect and analyze the data. Each quenched
reaction was injected onto an Agilent Technologies Zorbax Rapid Resolution
XBD-C18 column (4.6 mm × 50 mm, 1.8 μM particle size).
The column was first equilibrated in 95% solvent A (0.1% formic acid)
and 5% solvent B (100% acetonitrile). From 0 to 2 min, a linear gradient
from 5% to 60% solvent B was applied. From 2 to 2.5 min, the gradient
was increased linearly from 60% to 100% solvent B. From 2.5 to 4.5
min, the gradient was decreased linearly to 5% solvent B and was then
held constant for an additional 5 min. A constant flow rate of 0.7
mL/min was used throughout the method. MIA-AMP and tryptophan were
detected using the single-ion monitoring (SIM) mode. The set fragmentor
voltages for MIA-AMP and for tryptophan were 135 and 130 V, respectively.
Analysis of the Reaction Containing NosI, NosJ, and NosK
The basic reaction mixture consisted of 25 mM HEPES, pH 7.5, 1 mM
CoA, and 400 μM NosJ in a total volume of 40 μL. For formation
of holo NosJ, 36.7 μM Ec holo ACP synthase,
prepared as previously described,[19,20] was included.
For formation of MIA-holo NosJ, 20 μM NosI, 2 mM ATP, 2 mM MIA,
100 mM MgCl2, and 36.7 μM Ec holo
ACP synthase was included. Control reactions had either ATP, MIA,
or NosI omitted. Assays were quenched with 0.2% TFA, pH 2.4, after
2 h at room temperature, and then analyzed by HPLC.Samples
were analyzed using the Agilent 1100 series HPLC ChemStation software.
A Zorbax 300 stable bond C18 5 μm 4.6 mm × 250 mm column
was used with three different solvents at a flow rate of 1.3 mL/min:
solvent A, 0.2% TFA, pH 2.4; solvent B, acetonitrile; and solvent
C, methanol. The column was equilibrated in 5% solvent B and 95% solvent
A, which was maintained for 30 s after injection. From 30 s to 4 min,
solvents B and C were increased to 39% and 9%, respectively. From
4 to 12 min, solvent C was increased to 11.8%, while solvent B was
held constant at 39%. From 12 to 22 min, solvent C was increased to
50%, while solvent B was held constant at 39%. From 22 to 25 min,
solvents B and C were held constant at 39% and 50%, respectively.
From 25 to 27 min, solvent B was increased to 100%. From 27 to 28
min, solvent B was held constant at 100%. From 28 to 29.5 min, solvent
B was decreased to 5%. From 29.5 to 32 min, solvent B was held constant
at 5%.
MS Analysis of NosI, NosJ, and NosK Reactions
The complete
reaction (Figure ,
panel 4) contained the following in a final volume of 400 μL:
300 μM NosJ, 18 μM holo ACP synthase, 25 μM NosI,
300 μM NosK, 25 mM HEPES, pH 7.5, 500 μM CoA, 1 mM ATP,
1 mM MIA, and 100 mM MgCl2. For some reactions, various
components of the complete reaction mixture were omitted as indicated
in the text and legend for Figure . The reaction corresponding to panel 1 contained 300
μM NosJ, 25 mM HEPES, pH 7.5, 400 μM CoA, and 100 mM MgCl2. The reaction corresponding to panel 2 contained 300 μM
NosJ, 25 mM HEPES, pH 7.5, 1 mM CoA, 100 mM MgCl2, and
18 μM Ec holo ACP synthase. The reaction corresponding
to panel 3 contained 300 μM NosJ, 20 μM NosI, 25 mM HEPES,
pH 7.5, 500 μM CoA, 100 mM MgCl2, 1 mM ATP, 1 mM
MIA, and 18 μM Ec holo ACP synthase. The reactions
were incubated at room temperature for at least 1 h before being frozen
and stored at −80 °C until ready for analysis.MS
analysis was performed on a Waters Q-TOF Premier quadrupole/time-of-flight
(TOF) mass spectrometer (Waters Corporation, Micromass Ltd., Manchester,
UK). Operation of the mass spectrometer was performed using MassLynx
software Version 4.1 (http://www.waters.com). Samples were introduced into the mass spectrometer using a Waters
2695 HPLC system. Separation was performed by gradient elution on
a Thermo BioBasic C4, 50 × 2.1 mm HPLC column. The mobile phases
used were 0.1% formic acid in deionized water (solvent A), and 0.1%
formic acid in acetonitrile (solvent B) at a flow rate of 0.2 mL/min.
The column was equilibrated in 2% solvent B, which was held constant
for 1 min after sample (15 μL) injection. From 1.0 to 2.0 min,
a linear gradient from 2% to 95% solvent B was applied, which was
held constant at 95% solvent B from 2.0 to 15.0 min. From 15.0 to
15.1 min, a linear gradient from 95% to 2% solvent B was applied,
which was held constant at 2% solvent B from 15.1 to 20.0 min. Data
acquisition was performed during the first 15 min of the run, whereas
the final 5 min was used for column re-equilibration. The nitrogen
drying gas temperature was set to 300 °C at a flow rate of 6
L/min. The capillary voltage was 2.8 kV. The mass spectrometer was
set to scan from 500 to 2500 m/z in positive ion mode, using electrospray ionization.
MS Analysis
of Trypsin-Digested NosK
The reaction mixture
consisted of 50 μM NosJ, 50 μM NosI, 500 μM NosK,
100 mM MgCl2, 2 mM ATP, 2 mM MIA, 25 mM HEPES, pH 7.5,
0.1 mM CoA, and 10 μM holo ACP synthase in a total volume of
30 μL. The reaction was incubated at room temperature for approximately
1 h and then quenched with 30 μL of 2× SDS-PAGE buffer.
A control reaction that lacked NosI was also prepared and treated
identically. NosK was separated from other proteins on a 12% SDS-PAGE
gel, and the corresponding band was excised. An in-gel trypsin digestion
was performed on the excised band with sequencing-grade lyophilized
trypsin and subsequently analyzed at the Penn State Proteomics and
Mass Spectrometry Core facility.Mass spectra of tryptic digests
were acquired using the default instrument parameters for the reflector
positive-ion detection over the 700–3000 m/z range, and the method was calibrated with a bovine
serum albumin tryptic digest standard (Protea Biosciences). Mass spectra
were opened in the Bruker FlexAnalysis, smoothed by Savitzky–Golay
filtering (0.2 m/z, 1 cycle), and
baseline-subtracted using Top-Hat filtering. The mass lists were generated
using a SNAP peak detection algorithm with a signal-to-noise threshold
set at 6 and using the averagine SNAP average composition. The peak
at m/z 1581.733 was selected for
TOF-TOF analysis to establish the modification position. The resulting
MS2 data were processed using the default parameters and
loaded into the Bruker Biotools application. The fragment ions were
identified based on the best match between the experimental mass spectra
and the peak assignments generated by the Sequence Editor within Biotools.
HPLC Analysis of NosK Acylation
The complete reaction
contained the following in a total volume of 30 μL: 250 μM
NosK, 50 μM NosJ, 25 μM NosI, 10 μM Ec holo ACP synthase, 2 mM ATP, 2 mM MIA, 100 μM CoA, and 25
mM HEPES, pH 7.5. For some reactions, various components of the complete
reaction mixture were omitted as indicated in the text and legend
for Figure . NosK
control consisted of 250 μM NosK, 100 mM MgCl2, and
25 mM HEPES, pH 7.5. The control acylated NosK reaction consisted
of 250 μM NosK, 50 μM NosJ, 10 μM Ec Holo ACP synthase, 2 mM ATP, 2 mM MIA, 100 μM CoA, and 25
mM HEPES pH 7.5. The NosK S102A reaction contained 250 μM NosK
S102A, 50 μM NosJ, 25 μM NosI, 10 μM Ec Holo ACP synthase, 2 mM ATP, 2 mM MIA, 100 μM CoA, and 25
mM HEPES pH 7.5. The reactions were in a total volume of 30 μL
and were incubated at room temperature for approximately 1 h. Before
analysis by HPLC, the reactions were quenched with 0.2% TFA pH 2.4.Samples were analyzed using the Agilent 1100 series HPLC ChemStation
software. A Zorbax 300 stable bond C18 5 μm 4.6 mm × 250
mm column was used with two different solvents: solvent A, 0.2% TFA
pH 2.4 and solvent B, acetonitrile flowed at 1.4 mL per minute. The
column was equilibrated in 45% solvent B and 55% solvent A, which
was maintained for 3 min after injection. From 3 to 13 min, solvent
B was increased to 57%. From 13 to 14 min, solvent B was increased
to 100%. From 14 to 16 min, solvent B was held constant at 100%. From
16 to 17 min, solvent B was decreased to 45%. From 17 to 18 min, solvent
B was held constant at 45%.
Crystallization and X-ray Structure Determination
of NosK
A concentrated stock solution of NosK, prepared as
described above,
was diluted to 9 mg/mL in 10 mM Tris–HCl, pH 8.4, containing
300 mM KCl. Clear rod-shaped crystals appeared within 2 to 3 weeks
at room temperature by using the hanging drop vapor diffusion method.
Trays were prepared by mixing 1 μL of protein solution and 1
μL of precipitating solution containing 1.6 M (NH4)2SO4, 0.1 M NaCl, 0.1 M HEPES, pH 7.5, and
equilibrating the drops against a 0.5 M LiCl well solution. Crystals
were removed directly from their drops with rayon loops with no further
cryoprotection and flash-frozen in liquid nitrogen.X-ray diffraction
data sets were collected at the Life Sciences Collaborative Access
Team (LS-CAT) beamline 21-ID-G at the Advanced Photon Source. Data
sets were processed using iMosflm[33] and
phased by molecular replacement using BALBES.[34] Manual model building with Coot,[35] using
the initial search model S. aureus MenH
(PDB accession code 2XMZ)[36] as a template, and refinement in PHENIX[37] and Refmac5[38] yielded
a final model consisting of residues 28–257, 91 water molecules,
and one sulfate anion. Figures were generated using the PyMOL molecular
graphics software package (Schrödinger LLC) and electrostatic
surface maps were obtained with the APBS software plugin.[39] Data collection and refinement statistics are
shown in Table S3.
Authors: K Philip Wojtas; Matthias Riedrich; Jin-Yong Lu; Philipp Winter; Thomas Winkler; Sophia Walter; Hans-Dieter Arndt Journal: Angew Chem Int Ed Engl Date: 2016-06-27 Impact factor: 15.336
Authors: Antonio C Ruzzini; Shiva Bhowmik; Katherine C Yam; Subhangi Ghosh; Jeffrey T Bolin; Lindsay D Eltis Journal: Biochemistry Date: 2013-08-09 Impact factor: 3.162
Authors: Joseph W LaMattina; Bo Wang; Edward D Badding; Lauren K Gadsby; Tyler L Grove; Squire J Booker Journal: J Am Chem Soc Date: 2017-11-21 Impact factor: 15.419
Authors: Manuel Montalbán-López; Thomas A Scott; Sangeetha Ramesh; Imran R Rahman; Auke J van Heel; Jakob H Viel; Vahe Bandarian; Elke Dittmann; Olga Genilloud; Yuki Goto; María José Grande Burgos; Colin Hill; Seokhee Kim; Jesko Koehnke; John A Latham; A James Link; Beatriz Martínez; Satish K Nair; Yvain Nicolet; Sylvie Rebuffat; Hans-Georg Sahl; Dipti Sareen; Eric W Schmidt; Lutz Schmitt; Konstantin Severinov; Roderich D Süssmuth; Andrew W Truman; Huan Wang; Jing-Ke Weng; Gilles P van Wezel; Qi Zhang; Jin Zhong; Jörn Piel; Douglas A Mitchell; Oscar P Kuipers; Wilfred A van der Donk Journal: Nat Prod Rep Date: 2020-09-16 Impact factor: 15.111